Thymosin β4 (Tβ4)

Muscle/RecoveryActin-sequestering peptide / researchExperimental

Also known as: Timbetasin, Full-length thymosin beta-4, Thymosin Alpha-4

Thymosin β4 (Tβ4), also called Timbetasin or Full-length thymosin beta-4, is an actin-sequestering peptide in the Wound Healing / Cytoprotective class. Thymosin beta-4 is a 43-amino-acid peptide and the principal G-actin sequestering protein in most mammalian cells, binding monomeric actin through its LKKTETQ motif and maintaining the unpolymerised pool that cells draw on to remodel their cytoskeleton.

Calculate Dose

For research use only.

Key Facts

CAS
77591-33-4
Molecular Weight (MW)
≈4963 g/mol
Half-life
Not well established in humans
FDA status
Not Approved
Evidence level
Clinical Trial Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
G-actin

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
8
Listed offers
12
Median price per mg (peptide vials)
$5.73/mg
Typical $4.61–$6.73/mg

By form

Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.

Open calculator · Compare vendors

Research summary

43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trials3 reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Thymosin β4 (Tβ4) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Thymosin β4 (Tβ4) dosage: no established human dose

Thymosin beta-4 has no established human dosage. The trials that gave it to people were a safety study of intravenous doses from 42 to 1,260 mg a day for 14 days in healthy volunteers, a phase 2 study of a 0.01–0.1% gel on venous leg ulcers, and phase 3 trials of eye drops for dry eye. None of them established an injected dose that works.

Clinical Trial Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: Thymosin beta-4 is a 43-amino-acid actin-binding protein studied for wound healing, cardiac repair and eye surface repair. People have received it intravenously in a safety study, as a skin gel and as eye drops. The intravenous study measured tolerability only, and the gel and eye-drop trials used concentrations, not injected amounts, so no injected human dose has been shown to work.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Thymosin β4 (Tβ4)
Human dosing establishedNo
RouteNot established for injection; studied intravenously, topically and as eye drops
Evidence levelClinical Trial Evidence
Last reviewed2026-11-07

Human research reported

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Thymosin β4 (Tβ4), one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Phase 1 safety study, intravenous (2010)Clinical trial · Randomized, placebo-controlled ascending-dose safety studyHealthy volunteers (4 cohorts of 10)42, 140, 420 or 1,260 mg as a single dose, then the same dose dailyIntravenousOnce daily14 daysWell tolerated, with no dose-limiting toxicity; safety and pharmacokinetics onlyA randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010.
Phase 2, venous stasis ulcers (NCT00832091)Clinical trial · Randomized, double-blind, placebo-controlled dose-escalation trialAdults with venous stasis ulcers (n=72)0.01%, 0.03% or 0.1% w/w gelTopicalOnce dailyUp to 84 daysSafety comparable to placebo; the authors suggested 0.03% may speed healingNCT00832091 — Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
ARISE-2 — phase 3, RGN-259 eye drops for dry eye (NCT02974907)Clinical trial · Randomized, placebo-controlled phase 3 trialAdults with dry eye syndrome (n=601)RGN-259 eye drop solution containing thymosin beta-4OphthalmicFour times daily28 daysResults are posted on ClinicalTrials.gov and not summarised hereNCT02974907 — Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2

Where sources disagree

  • Thymosin beta-4 and TB-500 are often sold as the same thing. TB-500 is a short fragment of this protein, so these trials are not evidence for TB-500, and TB-500 protocols are not evidence for thymosin beta-4.
  • The intravenous doses of 42–1,260 mg were a tolerability range in healthy volunteers, not an effective dose.

Reconstitution

Common research vial sizes: 5 mg, 10 mg, 20 mg.

Reconstitution arithmetic for Thymosin β4 (Tβ4)
VialBacteriostatic waterConcentrationPer 0.01 mL
5 mg2 mL2.5 mg/mL25 mcg per 0.01 mL
10 mg2 mL5 mg/mL50 mcg per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Handling & administration

Timing Notes
Regulatory agencies note TB-500 is not approved for human therapy.

Sequence & molecular data

Sequence and molecular data for Thymosin β4 (Tβ4)
Molecular formulaC212H350N56O78S
Molecular weight≈4963 g/mol
CAS number77591-33-4
Half-lifeNot well established in humans
AppearanceWhite lyophilized powder
FormulationLyophilized Powder
PubChem CID45382195

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Thymosin beta-4 is a 43-amino-acid peptide and the principal G-actin sequestering protein in most mammalian cells, binding monomeric actin through its LKKTETQ motif and maintaining the unpolymerised pool that cells draw on to remodel their cytoskeleton. That function underlies its effects on cell motility, since directed migration requires rapid local actin polymerisation. Beyond actin binding it has been reported to promote angiogenesis, upregulate laminin-5, downregulate inflammatory cytokines, and reduce apoptosis in injured tissue. It has been investigated in dermal, corneal and cardiac repair. It is not approved for any use and is prohibited in sport.

Origin

Endogenous 43-aa peptide; synthetic research material.

Targets

G-actin

Research statistics

966 PubMed publications · 8.6% human clinical research · 16 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted · Human evidence quality, claim by claim

Regulatory & research status

Thymosin β4 (Tβ4) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Thymosin β4 (Tβ4)
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Banned in Sport
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Wound and cardiac-repair research

Thymosin β4 (Tβ4) side effects

The effects below are those reported in Thymosin β4 (Tβ4) clinical trials; long-term safety data may still be limited.

Side Effects

  • Limited human AE data for research vials

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Thymosin β4 (Tβ4): frequently asked questions

What is Thymosin β4 (Tβ4)?

43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment.

How does Thymosin β4 (Tβ4) work?

Thymosin beta-4 is a 43-amino-acid peptide and the principal G-actin sequestering protein in most mammalian cells, binding monomeric actin through its LKKTETQ motif and maintaining the unpolymerised pool that cells draw on to remodel their cytoskeleton. That function underlies its effects on cell motility, since directed migration requires rapid local actin polymerisation.

Is Thymosin β4 (Tβ4) FDA approved?

No. Thymosin β4 (Tβ4) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of Thymosin β4 (Tβ4)?

Reported half-life for Thymosin β4 (Tβ4) is Not well established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Thymosin β4 (Tβ4) banned in sport?

Thymosin β4 (Tβ4) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

What peptides are similar to Thymosin β4 (Tβ4)?

Compounds most often compared with Thymosin β4 (Tβ4) include BPC-157, TB-500 (Thymosin Beta-4 fragment), Pentadeca Arginate and GHK-Cu (Copper Peptide). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Thymosin β4 (Tβ4) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Thymosin β4 (Tβ4) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →